While established data now exist for anti-PD-1-based immunotherapy in the treatment of high-risk stage II melanoma, data are still lacking on the value of targeted therapies (i.e., BRAF inhibitors and MEK inhibitors). This evidence concerns the gene BRAF and melanoma.